Search Results

Introduction G protein-coupled receptors (GPCRs) don't simply switch on or off. Most are pleiotropically coupled to multiple intracellular pathways, and different ligands at the same receptor can produce fundamentally different cellular outcomes, a phenomenon known as GPCR signaling bias, or functional selectivity. Two molecules with identical binding affinity can diverge sharply in their downstream effects: one emphasizing G protein activation, another driving receptor internalization and β-arrestin recruitment, each producing a distinct pharmacological fingerprint. Measuring GPCR signaling bias in drug discovery is critical, as it forms a selection criterion for agonism. Measuring and quantifying signaling bias reveals which candidates emphasize therapeutically beneficial pathways, and which may be falsely characterized as equivalent by single-pathway assays. Drug discovery programs that do not consider investigating for signaling bias often fail to fully understand the distinction and risk candidate molecules from advancing along the pipeline. In this article, you'll learn: Four reasons why bias measurements improve candidate selection at every stage of the discovery pipeline How biased ligands can emphasize beneficial signaling pathways, and actively suppress harmful ones How bias can expand pursuit of targets previously considered too toxic or undruggable Why measuring signaling bias across multiple pathways gives a more accurate picture of true molecular selectivity Obtaining a GPCR Pathway Pharmacological Fingerprint To obtain a pharmacological fingerprint (or profile) for GPCR therapeutics, it is best to show how signaling bias and receptor selectivity can be quantified using cell-based assays. These assays offer a simple approach to the comparison of agonist profiles across different pathways and biased signaling. For example, Figure 1 shows cell-based assay results from the cAMP G protein activation pathway and the β-arrestin recruitment pathway for several incretins (metabolic hormones and therapeutics) acting on GLP-1 and GIP receptors. Both assays provide unique profiles and a preferred receptor signaling bias for the therapeutics tested. Figure 1. Dose-response curves for incretin agonists on GLP-1 and GIP receptors. Comparison of the curves reveals the relative selectivity of retratutide for GLP-1 receptor over GIP receptor compared to tirzepatide and yields sufficient data to calculate the signaling bias of the agonists for β-arrestin over cAMP responses. This data is calculated from the estimated max and EC50. How GPCR Signaling Bias Strengthens Drug Discovery Programs There are four distinct reasons why bias measurements improve drug discovery outcomes. Bias can make better drugs by emphasizing beneficial signaling pathways and de-emphasizing harmful ones. Opioid receptors offer clear illustration of this: G protein-biased agonists at the μ-opioid receptor have been explored as a strategy to preserve analgesia, while reducing β-arrestin-dependent adverse effects such as respiratory depression and constipation (Raehal et al., 2005; DeWire et al., 2013). Another example is at the angiotensin AT1 receptor, biased ligands like TRV120027 block deleterious vasoconstriction, while engaging β-arrestin signals that provide beneficial effects in heart failure (Violin et al., 2010). Bias measurements can identify structurally differentiated hits from high-throughput screens. Two hits from a primary screen may appear equivalent in a single-pathway assay but diverge significantly when tested in orthogonal functional assays. Counter-screening in biased assays distinguishes molecules that are genuinely different on a molecular level, and therefore more likely to produce distinct phenotypes in complex therapeutic models. Bias reduces complex efficacy profiles to measurable, optimizable scales for medicinal chemistry. Efficacy (comprising of both quality and quantity attributes for different agonists) reveals how an expected overall cellular response can be achieved from cellular signals. The quality attribute can be captured by bias measurements allowing for the reduction of complex phenotypes to graded activation of signaling pathways. Once a favorable efficacy fingerprint is identified in therapeutic cells (through cell-based assays), medicinal chemists can work backward to amplify or tune the relevant bias. Bias measurements are essential for accurate selectivity profiling. Quantifying bias offers a way to determine selectivity based on all known signaling for a given molecule. For instance, a compound that appears highly selective at a target receptor based on cAMP readouts alone may show far less selectivity when β-arrestin signaling is included. The β2-adrenoceptor bronchodilator clenbuterol, for example, exhibits 500-fold selectivity for β2 over β1 receptors in cyclic AMP assays, but exhibits a reduced selectivity (approximately 5.7-fold) when β-arrestin-mediated effects are measured (Casella et al., 2011). Without multi-pathway assays, selectivity assessments can be misleading. Emphasizing Beneficial and De-emphasizing Harmful Signaling Pathways One of the most powerful applications of GPCR biased signaling is the ability to separate therapeutic effects from adverse ones at the receptor level, not achieved with binary pharmacology. As different ligands stabilize different receptor conformations, it is possible to design molecules that selectively engage the beneficial pathways over harmful ones. The opioid system offers a highly studied example. Morphine provides effective analgesia but carries debilitating side effects including respiratory depression. Studies in β-arrestin knockout mice demonstrated that morphine produces significantly less respiratory depression in the absence of β-arrestin 2 signaling — pointing directly to a G protein-biased opioid agonist as a potentially superior analgesic, one that preserves pain relief while reducing a life-threatening adverse effect (Raehal et al., 2005; DeWire et al., 2013). The angiotensin system illustrates a more nuanced application: not just de-emphasizing a harmful pathway but blocking it while simultaneously preserving a beneficial one. In congestive heart failure, elevated angiotensin signaling raises arterial pressure resulting in the failure of the myocardium. Standard angiotensin receptor blockers like losartan address this, but at the cost of eliminating beneficial β-arrestin-mediated signals. Biased ligands such as TRV120027 block the deleterious G protein-driven effects, while retaining the beneficial β-arrestin signals offering a meaningfully improved therapeutic profile (Violin et al., 2010). Expanding the Druggable Target Space Through Bias Beyond refining the pharmacology of established targets, biased signaling can rehabilitate entire target classes previously considered too toxic to pursue. The κ-opioid receptor illustrates this directly. κ-Opioid agonists carry genuine therapeutic potential in mood, cognition, and addiction but also produce serious dysphoria, which has historically precluded clinical development. Biased κ-opioid agonists that reduce dysphoric signaling, while preserving beneficial effects, offer a route into a target class that unbiased pharmacology cannot safely access (White et al., 2014). Rather than abandoning a target because of a harmful pathway, bias offers a different answer: design around the liability. Conclusion Bias measurements reveal that efficacy has quality as well as quantity attributes, and that quality can be engineered. A biased ligand can be designed to favor pathways. For example, a pathway that build bones, relieve pain, or stabilize a failing heart, while avoiding pathways that cause respiratory depression, dysphoria, or dangerous arterial pressure. In the case of κ-opioid agonists, bias may be the only route by which an otherwise excluded target class becomes clinically viable at all. Bias quantification increases the value of known lead compounds, sharpens selectivity assessments, and provides medicinal chemists with graded, optimizable scales to work from. Programs that characterize signaling bias early — across G protein, β-arrestin, and second messenger pathways through cell-based assay assessments — carry forward candidates whose vivo behavior can be fully understood providing a meaningful selection criteria and competitive advantage at every stage of drug discovery. Eurofins DiscoverX provides the largest portfolio of GPCR assays and a unique service that utilizes state-of-the-art tools developed by Professor Terry Kenakin at the University of North Carolina School of Medicine for characterization of ligand bias. With the appropriate β-arrestin, internalization, and second messenger assays to quantify selective response and statistical tools to scale these effects, harnessing bias to produce selective ligands is now made simple. For further reading on GPCR biased signaling and assay methodologies, explore the ‘Insights into GPCR Drug Discovery and Development’ eBook and ‘GPCR Functional Cell-based Assays – Assessing Biased Signaling of Agonists’ White Paper by Kenakin, T. et al. (2025). Visit Eurofins DiscoverX GPCR Products and Solutions to explore the full portfolio of GPCR assays from Eurofins DiscoverX. References Raehal, K.M., Walker, J.K., & Bohn, L.M. (2005). Morphine side effects in beta-arrestin 2 knockout mice. Journal of Pharmacology and Experimental Therapeutics, 314(3), 1195–1201. https://doi.org/10.1124/jpet.105.087254 DeWire, S.M., Yamashita, D.S., Rominger, D.H., Liu, G., Cowan, C.L., Graczyk, T.M., … Violin, J.D. (2013). A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. Journal of Pharmacology and Experimental Therapeutics, 344 (3), 708–717. https://doi.org/10.1124/jpet.112.201616 Violin, J.D., DeWire, S.M., Yamashita, D., Rominger, D.H., Nguyen, L., Schiller, K., … Lark, M.W. (2010). Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. Journal of Pharmacology and Experimental Therapeutics, 335 (3), 572–579. https://doi.org/10.1124/jpet.110.173005 Casella, I., Ambrosio, C., Grò, M.C., Molinari, P., & Costa, T. (2011). Divergent agonist selectivity in activating β1- and β2-adrenoceptors for G protein and arrestin coupling. Biochemical Journal, 438 (1), 191–202. https://doi.org/10.1042/BJ20110374 Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., & Novick, S. (2012). A simple method for quantifying functional selectivity and agonist bias. ACS Chemical Neuroscience, 3 (3), 193–203. https://doi.org/10.1021/cn200111m Kenakin, T. (2019). Biased receptor agonism. Annual Review of Pharmacology and Toxicology, 59, 245–267. https://doi.org/10.1146/annurev-pharmtox-010818-021139

A Result That Looks Clean but Isn't That interpretation may be wrong. Not because the assay failed technically, but because of what steady-state measurement structurally cannot reveal when two opposing activities are present in the same scaffold. This is the kinetic detection problem in multi-target GPCR activity, and it has consequences for how scaffolds are interpreted at early stages of discovery. What This Article Does Not Cover From This Week's Lesson The kinetic detection argument is one piece of the lesson. The lesson also works through: Why certain disease architectures require multi-target engagement in the first place, and the therapeutic contexts where single-receptor pharmacology is a precision mismatch Hybrid ligand design: how two pharmacophores are encoded into one scaffold, and why a uniform PK profile changes what co-administration cannot achieve How amino acid substitution within incretin peptide sequences shifts receptor selectivity across GLP-1, GIP, and glucagon receptor types The two-edged character of multi-target engagement: why therapeutic breadth and side effect liability advance together The detection problem examined in this article is the final piece. It is also the one most consequential for how multi-target compounds are evaluated once they exist. The Steady-State Cancellation Problem A scaffold carrying both agonist and antagonist activity presents a detection problem that standard assays are not designed to resolve. At steady state, the assay captures the net effect of whatever the compound is doing at equilibrium. If the agonist activity and the antagonist activity in the scaffold are roughly balanced, the net effect approaches zero. The readout is flat. The compound appears inert. Nothing in the steady-state result signals that two active processes are cancelling each other. The data is not incorrect. It is incomplete in a way the assay cannot disclose by design. Dynorphin A is a case that makes this concrete. The peptide sequence carries a region responsible for efficacy and a separate region that functions as a binding address. If a fragment loses the efficacy-bearing portion, what remains is an antagonist. In a preparation containing both the full agonist and the antagonist fragment, steady-state observation would reveal only a progressive reduction in response as the ratio of antagonist increases. The underlying dual activity remains invisible. What Kinetics Surfaces Agonist and antagonist activity do not proceed at the same rate. Onset kinetics differ. And those differences, invisible at equilibrium, become visible in real-time observation. When a scaffold carries both activities, kinetic assays produce complex time-dependent response curves. An initial agonist response emerges first. Then the antagonist effect, developing at a different rate, begins to modify it. The curve shape is not noise. It is a pharmacological signature of two processes with different temporal profiles. Dr. Kenakin describes this in the session: "You will see these complex curves. You see agonism, but then you'd start to see the other effect kick in. Kinetically, however, you might see it." Ambenonium demonstrates this with unusual clarity. The compound is simultaneously a muscarinic receptor inhibitor and a cholinesterase inhibitor, two activities that oppose each other functionally. At steady state, the effects cancel, and the compound appears to have no net action. In real-time observation, both activities emerge as distinct, time-separated signatures: one potentiating acetylcholine through cholinesterase inhibition, the other attenuating the response through receptor blockade. The compound is not inactive. It is pharmacologically complex in a way that steady-state measurement assigns no value to. What This Means for Multi-Target Programs The implication is practical. A scaffold that reads as inactive under standard screening conditions may carry multiple activities that are cancelling at equilibrium. Dismissing it on the basis of that result forecloses something that kinetic investigation might recover. The broader point is a methodological one. Steady-state assays answer the question they are designed to answer: what is the net effect at equilibrium? They are not designed to disaggregate that net effect into its components. When a multi-target scaffold is the subject of investigation, the question being asked and the information the assay returns may not match. Kinetic approaches reframe the question. Rather than asking what the compound's net effect is, they ask how the compound's effects develop over time. That reframing is what makes the underlying pharmacological complexity visible. Why Terry's Corner The kinetic detection argument is one piece of what the session covers. The lesson develops the surrounding framework: why certain disease architectures require multi-target engagement in the first place, the design strategies for building it into a single scaffold, and how peptide sequence modification shifts receptor selectivity in predictable directions. The detection problem examined here is the final piece, and the one most consequential for how multi-target compounds are evaluated once they exist. Terry's Corner is the room where pharmacologists work through frameworks like these alongside Dr. Terry Kenakin. Structured lessons are the foundation. Live AMAs and workshops are where the thinking comes alive, and where the question you've been sitting on finally has somewhere to go. 🟢 40 years of expertise at your fingertips: Explore the complete library ➤ ✳️ Want to know what's inside? Read the latest articles ➤ Stay sharp between lectures. Subscribe to The Kenakin Brief today ➤ Follow the thinking. Terry's Corner on LinkedIn ➤ Check out the YouTube Channel. Terry's Corner on YouTube ➤

A Specific Difficulty, Not a General Verdict A pharmacologist designing an orthosteric small-molecule agonist for a family B GPCR encounters a pattern that recurs often enough to deserve a structural explanation. The molecule binds. The affinity is reasonable. The activation is weaker than the receptor's natural peptide agonist suggests it should be. The pattern is not universal, and it does not mean the orthosteric site is undruggable. It does mean that stabilizing the receptor's active state through a small molecule, at this specific class of GPCRs, is harder than orthosteric small-molecule programs at smaller receptors have led the field to expect. The reason has a structural account. It is one model among several, but it explains the observation cleanly, and it has practical consequences for how programs at peptide receptors approach modality choice. What GPCR Biologic Drugs Reveal About the Active-State Problem Family B GPCRs are conformationally malleable. The receptor samples many states. To produce agonism, a ligand must do more than occupy the binding pocket. It must stabilize the active conformation specifically, long enough for downstream signaling to proceed. GPCR biologic drugs, peptides in particular, achieve this through a mechanism worth naming carefully. A peptide agonist makes contact with the receptor across numerous regions of the binding site. Each contact contributes modestly. Together, they form what receptor pharmacologists describe as affinity traps: distributed networks of interactions that hold the receptor in an active state by satisfying many constraints at once. The active state is, on this account, the conformation in which the largest number of those contacts are simultaneously engaged. The peptide does not pull the receptor into activation. It selects for it, through the geometry of where its contacts can reach. Why an Orthosteric Small Molecule Has a Harder Time A small molecule binding the same orthosteric site engages fewer of those contact points. Not because small-molecule chemistry is weaker, but because a small molecule, by definition, occupies less of the binding region than a peptide does. This model suggests the consequence. The small molecule can show affinity for the site. It can produce binding. What it has more trouble doing is stabilizing the specific active conformation that the full peptide contact network selects for. The orthosteric site is the same site. The conformational outcome accessible from it depends on how much of the binding architecture a ligand can engage at once. Dr. Kenakin frames this carefully in the lecture: an orthosteric small molecule binds in only a few of the regions a peptide engages, and on this model, it will not stabilize the active state the same way. The framing is "seems to be difficult." Not impossible. Not categorically excluded. Difficult, for a reason that is structural rather than chemical. Why Allosteric Modulation Is the Productive Route The same structural account points toward the alternative that has been productive at these targets. An allosteric modulator does not need to engage the orthosteric contact network at all. It binds at a separate site, often on the receptor's extracellular surface or within a transmembrane domain, and influences the receptor's conformational equilibrium from there. The active state can be stabilized through a different geometric route, one that does not require the small molecule to reach across the full peptide binding region. Family B GPCRs have a rich history of allosteric ligands that produce activation. The argument is not that orthosteric small molecules are wrong at these receptors. It is that allosteric chemistry has a structural advantage when the goal is stabilizing an active state at a receptor whose natural agonist is a peptide. What This Means for Program Decisions The affinity-trap account, treated as a model rather than a verdict, has practical implications. It suggests that the difficulty an orthosteric small-molecule agonist program encounters at a family B GPCR may be a feature of the geometry, not a flaw in the chemistry. A series that shows good binding and weak activation, repeatedly, may be encountering the limit of what a small molecule can do at a site optimized over evolutionary time for peptide engagement. It also suggests that allosteric modulation deserves earlier consideration than it sometimes receives at these targets, and that biologic modalities, including peptides themselves, occupy a structural space orthosteric small molecules are not well positioned to fill. These are framing decisions, not prescriptions. The orthosteric site at a family B GPCR is not closed to small molecules. It is, on the affinity-trap account, a more difficult place to produce agonism than the same kind of site at a receptor whose natural ligand is itself small. Why Terry's Corner The affinity-trap account is one framework. The lesson it comes from develops what follows: biased signaling at peptide receptors, antibody-driven control of receptor disposition, the ADME and safety profile GPCR biologic drugs inherit, and the trafficking decisions that determine receptor fate inside the cell. These are pharmacological frameworks, and small-molecule intuition does not transfer cleanly to all of them. Terry's Corner is the room where pharmacologists work through frameworks like these alongside Dr. Terry Kenakin, with structured lessons as the foundation and live AMAs and workshops where the thinking comes alive. This is where receptor pharmacologists who take interpretation seriously sharpen their thinking together. 🟢 40 years of expertise at your fingertips: Explore the complete library ➤ ✳️ Want to know what's inside? Read the latest articles ➤ Stay sharp between lectures. Subscribe to The Kenakin Brief today ➤ Check out the YouTube Channel. https://www.youtube.com/@TerryPharmacologyCorner➤

Explore the world of GPCRs with Dr. GPCR Podcast! Join industry leaders as they share insights, stories, and groundbreaking discoveries, enriching our understanding of GPCRs. Delve into the science behind these vital components shaping our collective knowledge. Welcome to the Dr. GPCR Podcast - The Voice of the Community Conversations with the world’s leading GPCR scientists. Exploring discoveries, careers, and ideas shaping human health. In each episode, we sit down with leading experts to explore their career journeys, groundbreaking discoveries, and the impact of their research on our shared understanding of GPCR biology. Launched at the height of the pandemic, the Dr. GPCR Podcast was created with three goals: Share discoveries – Highlight the latest advances in the GPCR field. Amplify voices – Provide scientists a platform to showcase their work. Inspire the future – Motivate the next generation to pursue GPCR research. At its core, Dr. GPCR’s mission is simple yet ambitious: to bring the GPCR community together - across borders and disciplines - to connect, exchange, and collaborate in order to improve human health through a deeper understanding of GPCR biology. Latest Podcast Episodes More podcast episodes Dr. GPCR Podcast Audience Survey We are currently planning our next season and need your help. This short survey will help us understand your needs to bring you exciting and informative content. We also know that you are busy, which is why we designed this short survey that should take you 5 minutes. Fill out this form Be our Guest In each episode, we chat with an expert about their career trajectory, discoveries, and how their research contributed to the shared pool of knowledge about GPCR biology. We’d love to have you on our podcast. To be a guest, fill out the form below, and we’ll be in touch in 48 hours. Fill out this form What others are saying about this podcast "You made it a very comfortable and engaging experience, and it felt like we were chatting over coffee — Yamina thoughtfully guided our chat throughout." Anita Nivedha I think it's really well done. I'm genuinely interested to see how it evolves and grows over time, as I feel it has the potential to develop into something even more impactful. Anonymous This came at just the most perfect time. I hadn't heard a scientific talk outside my lab since February and was starved to hear someone else talk passionately about GPCRs. I've listened to the episodes multiple times and it's just like being at a conference getting new ideas. I just couldn't be happier y'all created this podcast. Anonymous Great initiative, thanks. Carrier paths, choosing research topics, switching fields, late start, failures and successes. Anonymous I enjoy the breadth of questioning that goes beyond just the science, and reveals a bit about the scientists as individuals/mentors/people. Anonymous Really enjoyable science podcast! Dr. Yamina Berchiche interviews leading GPCR scientists on this vibrant, entertaining podcast. I really appreciate the way the podcast educates and mentors, particularly towards junior scientists but also to the community as a wholen Yamina is a great interviewer, getting insight and personal history from her guests. Am very grateful for Dr GPCR livening up the week in these difficult times! Sam @Pharmamechanic Listen and subscribe where you get your podcasts

Explore upcoming GPCR Masterclass live sessions featuring expert discussions on GPCR pharmacology, receptor biology, and drug discovery. University / Live Masterclass Sessions In the room with the scientist, not watching from the audience. Live scientific exchanges with leading GPCR experts. Interactive, question-driven, frontier science. This isn't a lecture — it's a conversation with the people shaping GPCR discovery. Masterclass is included inDr. GPCR University Try it for 14 days Upcoming live sessions Your next Live Masterclass Session is waiting Each session focuses on a specific pharmacology or GPCR discovery topic, led by a recognized expert. Live Q&A means your questions get real answers. June 11, 2026 Dr. Jakob Höppner | Harvard University | MGH Subcellular Regulation of PTH1R Signaling Translational Pharmacology & Disease Models Details October 8, 2026 Dr. Marsha Pierce | Midewestern University Introduction to GLP-1 pharmacology Details June 18, 2026 Dr. Dmitry Veprintsev | U. of Nottingham Postponed | Biophysical approaches to study orphan GPCR ligand binding and signalling Details 1 1 ... 1 ... 1 What makes this different? Not a lecture. Not a webinar. A scientific exchange. The Masterclass was created because the most valuable insights in GPCR science aren't captured in papers or conference talks. Scientist-to-scientist discussion Extended Q&A allows deeper exploration than typical presentations. You're engaging directly with the expert — not submitting a question to a moderator. Beyond conference time limits Topics are explored in greater depth than standard conference talks allow. Sessions focus on scientific reasoning, data interpretation, and real discovery problems. Focused audience of specialists Sessions bring together GPCR researchers, pharmacologists, and discovery scientists. The conversation stays at the right level because everyone in the room speaks the same scientific language. Every session recorded Can't make it live? Every Masterclass is recorded and available on demand in the library. Revisit the science anytime — over 200 sessions and growing. On-demand library 200+ expert sessions, available anytime Full recordings of every Masterclass session. Revisit the science at your pace — filter by category, level, or instructor. Andrew Tobin How to Build Breakthrough GPCR Programs Sudarshan Rajagopal The Spatiotemporal Revolution in GPCR Biology Sam Hoare How Signaling Kinetics Shapes GPCR Drug Action Explore all Recorded Masterclasses → The scientists Learn directly from world leaders in GPCR research Andrew Tobin Marsha Pierce Terry Hébert Bryan Roth Matteo Pavan Terry Kenakin Jakob Höppner Samuel Hoare Yamina Berchiche Kenneth Jacobson Sudarshan Rajagopal What scientists say? From the people in the room Dr. Hoare is very experienced in the field. What came as a pleasant surprise was how didactical and well-thought-out his course was—highly recommended. The really unexpected was that the Q&A sessions reached the highest level—beyond excellent. I am a convert! I will keep Dr. GPCR and the offered resources in my work sphere GPCR researcher Thank you for bringing this course with Dr. Kenakin. I wish Dr. GPCR the best for the sake of promoting more educational opportunities that are sorely needed in the field GPCR researcher The content had enough depth to satisfy the hunger for theory while being full of practical knowledge GPCR researcher The best pharmacology teacher teaming up with the best GPCR community platform to help train and inspire the next generation of scientists. Also super-valuable for those of us learning how to teach pharmacology GPCR researcher Dr. Hoare's extensive and elaborative explanation of the topics at hand was excellent and very digestible. Thoroughly enjoyed learning from him GPCR researcher Dr. Kenakin is a leading expert in the field. Aside from his vast experience in drug development, not to mention his extensive publication record, Dr. Kenakin is a masterful teacher and communicator. GPCR researcher The course was very practical and easily translatable to experiments that we could do in our own labs. It was clear that Dr. Hoare is very in touch with the technical and human challenges we encounter in our work GPCR researcher About the GPCR Masterclass What is a GPCR Masterclass? The GPCR Masterclass is a live scientific discussion with a leading expert in GPCR pharmacology, receptor biology, or drug discovery. Sessions focus on research questions, experimental interpretation, and emerging challenges in GPCR science. Are the sessions live or recorded? Masterclass sessions are conducted live with an invited expert. After the event, recordings are added to the Masterclass course library, where Premium Members can access them on demand. Who should join? The Masterclass is designed for GPCR researchers, pharmacologists, and drug discovery scientists working in academia, biotech, and pharmaceutical research. Can I watch sessions later if I miss the live event? Yes. All sessions are recorded and available in the Masterclass course library for Premium Members. Can I watch sessions later if I miss the live event? Yes. All sessions are recorded and available in the Masterclass course library for Premium Members. How do I fit this in my schedule? You can attend the live discussion or watch the recording later. The Masterclass library allows members to revisit sessions at any time. What makes the Masterclass different from reading papers or textbooks? The Masterclass focuses on scientific interpretation and discussion. Experts explain how they think about pharmacological data, experimental design, and discovery challenges—insight that is rarely captured in publications. What happens during the live discussion? Each session begins with a focused presentation from the guest expert, followed by moderated discussion and questions from participants. The format allows deeper exploration of pharmacology concepts than typical conference presentations. Masterclass is included in Dr. GPCR University Live sessions, 200+ on-demand recordings, plus premium intelligence, jobs, events, and a community of GPCR scientists — all in one place. See what it feels like for 14 days. Try University for 14 days — $50 Your professional home in GPCR science. $499/year after trial.

Articles News Get in Touch Item List This is a Title 01 This is placeholder text. To change this content, double-click on the element and click Change Content. Read More This is a Title 02 This is placeholder text. To change this content, double-click on the element and click Change Content. Read More This is a Title 03 This is placeholder text. To change this content, double-click on the element and click Change Content. Read More Menu • Home • Services • About Ready to collaborate? Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution across biotech, VC, and CRO teams. Get in touch ©2023-2025 All rights reserved by FindYooour, LLC & Dr. GPCR Corp Proudly created with Wix.com Connect • LinkedIn • Podcast • Dr. GPCR Ecosystem